Business Context and Reporting Period
This Form 8-K Current Report was filed by Emerald Bioscience, Inc. (not Skye Bioscience, Inc.) on August 12, 2020, covering events that occurred on August 7, 2020. The filing details significant changes in corporate governance and management, including the departure of the CEO and the appointment of new leadership.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and governance changes.
Material Changes
- Departure of CEO: Brian Murphy resigned as Chief Executive Officer and Board member effective August 7, 2020.
- Appointment of New CEO: Punit Dhillon was appointed Chief Executive Officer effective August 7, 2020. He remains Chairman of the Board.
- Board Expansion: Dr. Margaret Dalesandro was appointed as an independent Director and assigned to multiple committees.
- Compensation Plan Amendment: The Board approved Amendment No. 2 to the 2014 Omnibus Incentive Plan, removing certain restrictions on share and cash-based awards.
Management Commentary and Compensation Details
Separation of Brian Murphy
- Severance: $195,000 gross salary continuation over six months.
- Benefits: Healthcare benefits for six months.
Employment of Punit Dhillon
- Base Salary: $400,000 annually.
- Bonus: Discretionary bonus up to 50% of base salary based on milestones.
- Equity Grant: Options to purchase 9,000,000 shares at $0.045 per share. 10% vested immediately; remaining 90% vests over 4.5 years.
- Severance: Minimum 6 months' pay if terminated without cause; increases to 12 or 24 months based on tenure milestones.
Appointment of Dr. Margaret Dalesandro
- Cash Fee: $52,500 annually.
- Equity Grant: Options to purchase 250,000 shares at $0.045 per share. 10% vested immediately; remaining 90% vests over 2 years.
Investor Verification Checklist
- Verify the full text of the Separation Agreement (Exhibit 10.1) and Employment Agreement (Exhibit 10.2) for specific definitions of "Cause," "Disability," and milestone criteria.
- Confirm the impact of the 9,000,000 share option grant to the new CEO on existing shareholder dilution.
- Review the specific restrictions removed in Amendment No. 2 to the 2014 Omnibus Incentive Plan (Exhibit 10.3).
- Check subsequent filings for the company's financial status, as this 8-K contains no operational or financial performance data.